long entry from $100; PT1 $125 PT2 $143

Q1 2019 - FDA meeting outcome on Sativex;

Sativex (nabiximols) is an oromucosal spray of a formulated botanical extract of cannabis
that contains the principal cannabinoids delta-9-tetrahydrocannabinol ( THC ) and cannabidiol ( CBD ) in a 1:1 ratio

Approved in >25 countries outside of the U.S. for the treatment of spasticity due to multiple sclerosis ( MS ); sold via marketing partners
• Three positive Phase 3 trials completed in Europe

U.S. development and commercialization plan
• Evaluating NDA path for MS spasticity
• Potential for multiple indications
• >10 additional placebo-controlled trials completed
• Significant U.S. life cycle management opportunities

EMA decision Q1 2019
Phase 3 TSC data Q2 2019
Dravet 2 data presentation Q2 2019
Rett syndrome Phase 3 study start Q2 2019
TSC FDA sNDA submission Q4 2019

FDA meeting outcome Q1 2019
Phase 3 MS study start 2H 2019

Cash at 30 September 2018
Net cash from October financing
Q ending 31 December 2018 operating expense guidance
Comment: Let this winner run!
Trade closed manually: Profits taken at 150. Watch on Q4 earnings. Epidiolex
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out